H.U. Group Holdings, Inc.

H.U. Group’s testing and related services measure specimens entrusted by medical institutions and report the results. Operating profit was ¥31m in the year ended March 2026. The company cites growth in genetic and specialized testing, price adjustments and improved testing operations. Segment depreciation was ¥13.598bn, showing the costs behind keeping equipment and people at work. Consolidated operating profit of ¥4.780bn covers a different scope, including diagnostic reagents, other businesses and corporate-cost adjustments.